Latest From Sucampo Group
With relatively few new drugs in development for opioid-induced constipation, the category is wide open for new entrants to conduct clinical studies and make a difference for patients; a Market Spotlight report from Datamonitor Healthcare reviews the indication's outlook.
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Sucampo Group
- Senior Management
Ryuji Ueno, MD, PhD, CEO & CSO
Ronald W Kaiser, CFO
Sachiko Kuno, PhD, Chmn. & Pres.
Kei S Tolliver, VP, Bus. Dev. & Co. Operations
Gayle Robert Dolecek, SVP, R&D
Stanley G Miele, SVP, Sales & Mktg.
- Contact Info
Phone: (81) 79-560-7181
4-1 Techno Park
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.